246 related articles for article (PubMed ID: 36913303)
1. Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.
Blagosklonny MV
Oncotarget; 2023 Mar; 14():193-206. PubMed ID: 36913303
[TBL] [Abstract][Full Text] [Related]
2. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer.
Saputra EC; Huang L; Chen Y; Tucker-Kellogg L
Cancer Res; 2018 May; 78(9):2419-2431. PubMed ID: 29686021
[TBL] [Abstract][Full Text] [Related]
4. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.
Blagosklonny MV
Leukemia; 2001 Jun; 15(6):936-41. PubMed ID: 11417480
[TBL] [Abstract][Full Text] [Related]
5. Prospective strategies to enforce selectively cell death in cancer cells.
Blagosklonny MV
Oncogene; 2004 Apr; 23(16):2967-75. PubMed ID: 15077157
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
8. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
9. Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal.
Blagosklonny MV
Leukemia; 1999 Dec; 13(12):2031-5. PubMed ID: 10602425
[TBL] [Abstract][Full Text] [Related]
10. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance.
Ng CP; Bonavida B
Adv Cancer Res; 2002; 85():145-74. PubMed ID: 12374285
[TBL] [Abstract][Full Text] [Related]
11. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer cells by exploiting their resistance.
Blagosklonny MV
Trends Mol Med; 2003 Jul; 9(7):307-12. PubMed ID: 12900218
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-resistant metastatic breast cancer.
Marquette C; Nabell L
Curr Treat Options Oncol; 2012 Jun; 13(2):263-75. PubMed ID: 22528367
[TBL] [Abstract][Full Text] [Related]
14. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
15. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.
Klinghoffer RA; Bahrami SB; Hatton BA; Frazier JP; Moreno-Gonzalez A; Strand AD; Kerwin WS; Casalini JR; Thirstrup DJ; You S; Morris SM; Watts KL; Veiseh M; Grenley MO; Tretyak I; Dey J; Carleton M; Beirne E; Pedro KD; Ditzler SH; Girard EJ; Deckwerth TL; Bertout JA; Meleo KA; Filvaroff EH; Chopra R; Press OW; Olson JM
Sci Transl Med; 2015 Apr; 7(284):284ra58. PubMed ID: 25904742
[TBL] [Abstract][Full Text] [Related]
16. How cancer could be cured by 2015.
Blagosklonny MV
Cell Cycle; 2005 Feb; 4(2):269-78. PubMed ID: 15655345
[TBL] [Abstract][Full Text] [Related]
17. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression.
Cheng J; Cashman JR
Invest New Drugs; 2021 Feb; 39(1):131-141. PubMed ID: 32915418
[TBL] [Abstract][Full Text] [Related]
20. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW
Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
